TAG:
the clinical laboratory
What’s New at Theranos? Lab Firm Expands in AZ
By Robert Michel | From the Volume XXII No. 6 – April 20, 2015 Issue
CEO SUMMARY: Over the past 18 months, Theranos has taken steps to enter the clinical lab marketplace. Across Greater Phoenix, Theranos now has specimen collection centers in about 40 Walgreens pharmacies. It is opening a CLIA lab facility in Scottsdale. Now that it is delivering…
Theranos: Many Questions, but Very Few Answers
By Robert Michel | From the Volume XXII No. 6 – April 20, 2015 Issue
CEO SUMMARY: Winston Churchill famously said that “Russia is a riddle wrapped in a mystery inside an enigma.” That description could apply to Theranos, the company that claims it is poised to disrupt the entire clinical laboratory testing industry. In Phoenix, where Theranos is r…
Theranos: Many Questions, but Very Few Answers
By Mary Van Doren | From the Volume XXII No. 6 – April 20, 2015 Issue
WHEN A COMPANY THAT GOES PUBLIC WITH ITS GOALS, regularly and repeatedly declaring its lofty ambitions to do good for mankind by disrupting the status quo and replacing it with something new and wonderful, it invites itself to be judged by its actions and what it actually delivers. Since Thera…
Pathologists Contribute To Care in Wisconsin ACO
By Joseph Burns | From the Volume XXII No. 5 – March 30, 2015 Issue
CEO SUMMARY: From the launch in 2013 of a big accountable care organization in Wisconsin, the North Shore Pathologists at Columbia-St. Mary’s Hospital have been involved. Among the lessons learned are the importance of structuring the pathology contract with the hospital to antic…
March 30, 2015 Intelligence: Late Breaking Lab News
By Robert Michel | From the Volume XXII No. 5 – March 30, 2015 Issue
Last Friday, at Geisinger Medical Center in Danville, Pennsylvania, members of the health systems’s authority board were given tours of the new $63.4 million clinical laboratory facility. It is scheduled to open on May 4 and will feature the latest state-of-the art analyzers and lab automation system…
Beware Ides of March! Lawmakers Are in Session
By Joseph Burns | From the Volume XXII No. 4 – March 9, 2015 Issue
CEO SUMMARY: Few pathologists and lab administrators know that, when the Protecting Access to Medicare Act of 2014 (PAMA) became law last April 1, language in the bill was scored to reduce Part B clinical laboratory test fees by $2.5 billion over 10 years. Congress used those lab…
Locked Out of Payer Network, NH Hospital Opens Lab Company
By Joseph Burns | From the Volume XXII No. 4 – March 9, 2015 Issue
CEO SUMMARY: Since Anthem launched its site of service program in New Hampshire in 2010, labs in the state’s hospitals have mostly been excluded from its network and have lost market share. Recently one community hospital developed an unusual strategy to win back those patients…
March 9, 2015 Intelligence: Late Breaking Lab News
By Robert Michel | From the Volume XXII No. 4 – March 9, 2015 Issue
Many laboratory professionals are closely watching the development of Theranos, the lab testing company based in Palo Alto, California, that claims it has technology and a business model that will disrupt the clinical laboratory testing market. Recently Forbes announced its annual li…
Achieving CLIA, ISO 15189 at Same Time with A2LA
By Joseph Burns | From the Volume XXII No. 3 – February 17, 2015 Issue
CEO SUMMARY: An interesting milestone for the clinical lab industry is on the horizon. Physicians Choice Laboratory Services in South Carolina will soon become one of the first lab organizations in the United States to earn joint CLIA and ISO 15189 accreditations with the America…
Market Price Report Rules Must Address All Issues
By Joseph Burns | From the Volume XXII No. 3 – February 17, 2015 Issue
CEO SUMMARY: Under the Protecting Access to Medicare Act, CMS must collect market price and volume data from certain labs beginning January 1, 2016. CMS will use this data to establish Part B clinical laboratory fees beginning in 2017. One lab association representing community a…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized